RESEARCH

Go to other sections:

RESEARCH ABSTRACTS PRESENTED AT SCIENTIFIC MEETINGS

11th Annual Canadian Conference on HIV/AIDS Research

Clinical Efficacy of Salvage Regimens Containing both Amprenavir (APV) and

Lopinavir/ritonavir (LPV/r) as Compared to Salvage Regimens Containing Only

LPV/r Stratified by NNRTI-Experience (abstract 210)

M Loutfy, C Thompson, M Trpeski, C Kovacs, A Rachlis, J Goodhew, G Rubin, K

Gough, S Walmsley

abstract:   <abs210.htm>

Virologic and Immunologic Responses of 281 ARV-Experienced Patients Enrolled

in the Lopinavir/ritonavir (LPV/r) Expanded Access Program (EAP) in Toronto,

Canada (abstract 237)

M Loutfy, C Thompson, M Trpeski, C Kovacs, A Rachlis, J Goodhew, G Rubin, K

Gough, S Walmsley

abstract:   <abs237P.htm>

Outcomes of Antiretroviral (ARV)-Experienced Patients Initiating a Salvage

Regimen Containing Amprenavir as the Protease Inhibitor (PI) (abstract 238)

M Loutfy, C Thompson, M Trpeski, A Rachlis, S Walmsley

abstract:   <abs238P.htm>

Lipid Profile Changes in 245 Patients on Lopinavir/Ritonavir (LPV/r) and the

Response of 45 of Those Patients to Lipid-Lowering Agents (LLAS)  (abstract

242)

M Loutfy, C Thompson, M Trpeski, C Kovacs, A Rachlis, J Goodhew, G Rubin, K

Gough, S Walmsley

abstract:   <abs242P.htm>

Comparison of Self-Obtained and Physician-Obtained Cervical Swab Samples for

Detection of Human Papillomavirus (HPV) DNA in Women Infected with HIV

(abstract 255)

F Coutlée, C Hankins, S Walmsley, D Money, K Pourreaux, P Forest, J-O Shu,

Canadian Women's HIV Study Group

abstract:   <abs255P.htm>

Pilot Study Investigating Feasibility of Standardized Sexual Function

Assessment Measures for Men Living with HIV (abstract 465)

PM Buckler, RW Burgoyne

abstract:   <abs465P.htm>

Physical, Mental and Social Wellbeing in Relation to HAART-Era Long-Term

Clinical Outcomes for Adult PHA (abstract 482)

RW Burgoyne

abstract:   <abs482P.htm>

 

9th Conference on Retroviruses and Opportunistic Infections, Seattle WA, February 24-28, 2002

The Use of Virtual Inhibitory Quotient (VIQ) in Antiretroviral (ART)-Experienced Patients Taking Amprenavir/Lopinavir Combinations (abstract 130)

E. Phillips, A. Tseng, M. Loutfy, S. Walmsley, S. Tailor, P. R. Harrigan, and S Walker.

abstract: http://63.126.3.84/2002/Abstract/13710.htm

Influence of Genotypic Resistance on the Viral Load Response of 167 Patients on Lopinavir/r (LPV/r) including an Analysis of New Protease Inhibitor Resistant Mutations in 21 Patients who Failed (abstract 560-T)

M. Loutfy, C. Thompson, M. Trpeski, C. Kovacs, A. Rachlis, J. Goodhew, G. Rubin, K. Gough, and S. Walmsley

abstract: http://63.126.3.84/2002/Abstract/13445.htm

poster: http://63.126.3.84/2002/Posters/13445.pdf

Tenth Annual Canadian Conference on HIV/AIDS Research, Toronto, May 31-June 3, 2001

Update in temporal trends in antiretroviral use among women participating in the Canadian Women's HIV Study [abstract 201]

Efficacy of ABT-378 as salvage therapy in heavily antiretroviral experienced patients in a clinic setting [abstract 211]  

A prospective study of body fat redistribution and metabolic abnormalities in patients initiating HAART [abstract 216].

    Walmsley S, Foster A, Raboud J, Cheung A, Fantas G, Clarke R, Smaill F, Gough K, Logue K.   

    abstract:  CAHR2001.abs216.pdf

CD36 deficiency induced by protease inhibitors:  a predictive role in lipodystrophy?  [abstract 217]. 

Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients who have responded to HAART [abstract 228].

    Walmsley S, Casiaro L, Mazzulli T, Gough K, Logue K, Rachlis A, Hopkins J.    .

    abstract:  CAHR2001.abs228.pdf 

Antiretroviral Prescribing Practices by Toronto Physicians for Treatment-Naïve Patients [abstract 232]. 

Comparing physician evaluation to patient self-assessment of the lipodystrophy syndrome

    EJ Collins1,2, RW Burgoyne1,2, CA Wagner4, ML Nur1, SL Walmsley1,3. 1Toronto General Hospital; 2Department of Psychiatry, 3Department of Medicine, University of Toronto; 4Primary Care Physician.

     Presented at the 10th Annual Canadian HIV/AIDS Research Conference, Toronto, May 31-June 2, 2001.

    abstract:  CAHR2001.abs273P.pdf

Lipodystrophy syndrome and health-related quality of life

    EJ Collins1,2, RW Burgoyne1,2, CA Wagner4, ML Nur1, SL Walmsley1,3. 1Toronto General Hospital; 2Department of Psychiatry,3Department of Medicine, University of Toronto; 4Primary Care Physician.  Presented at the 10th Annual Canadian HIV/AIDS Research Conference, Toronto, May 31-June 2, 2001.

    abstract: CAHR2001.abs218.pdf

Prospective utility of mos sf-36 quality-of-life physical and mental component summary scales in hiv-infection

    RW Burgoyne1, 2, SB Rourke1, 3. 1Department of Psychiatry, University of Toronto; 2Toronto General Hospital Immunodeficiency Clinic; 3St Michael's Hospital Inner City Health Program, Mental Health Service (HIV Psychiatry Program) and Inner City Health Research Unit, Toronto, Ontario, Canada.  Presented at the 10th Annual Canadian HIV/AIDS Research Conference, Toronto, May 31-June 2, 2001.

    abstract: burgoyne.PROSPECTIVE UTILITY OF MOS SF.doc

The effects of age and clinical outcome on health-related quality-of-life among pha on highly active anti-retroviral therapy

    RW Burgoyne, DS Saunder, IE Salit1,4. 1Toronto General Hospital; 2Department of Psychiatry; 3Department of Public Health Sciences; Department of Medicine, University of Toronto, Toronto, Canada.  Presented at the 10th Annual Canadian HIV/AIDS Research Conference, Toronto, May 31-June 2, 2001.

    abstract: burgoyne.THE EFFECTS OF AGE.doc

8th Conference on Retroviruses and Opportunistic Infections, Chicago IL. February 4-8, 2001

Effectiveness of antiretroviral therapy in the elderly compared to a younger cohort [abstract 340]

CD4+ cell count is a better predictor of disease progression than hiv rna level in persons with advanced hiv infection on highly active antiretroviral therapy [abstract 203]

CD36 deficiency induced by antiretroviral therapy:  a predictive role in lipodystrophy [abstract 667].

13th International AIDS Conference, Durban, South Africa. July 9-14, 2000

A pilot study of nelfinavir therapeutic drug monitoring in HIV-infected patients [abstract TuPeB3300]

    Tseng A, Patel M, Gallicano K, Khaliq Y, Walmsley S.  .  Presented at the 13th International AIDS Conference, Durban, South Africa.  July 9-14, 2000.

    abstract: abstract3.durban00.doc

    poster: nfv-tdm.durban00.pdf

Development of an HIV specialty pharmacy residency program [abstract WePpD1327]

    Tseng A, Foisy M, Bajcar J, Musing E, Wells J, Grondin M, Salit I. . Presented at the 13th International AIDS Conference, Durban, South Africa.  July 9-14, 2000.

    abstract: AIDS00.abstract.doc

    poster: hiv residency.durban00.pdf

Prior non-nucleoside reverse transcriptase inhibitor failure impairs virologic responses to salvage therapies including efavirenz [abstract WePeB4155].

    Walmsley S, Chantler P, Tseng A, Harrigan PR.   Presented at the 13th International AIDS Conference, Durban, South Africa.  July 9-14, 2000.

    poster:  nnRTI.durban00.walmsley.pdf

9th Annual Canadian Conference on HIV/AIDS Research, Montreal, PQ. April 27-30, 2000

Probable interaction between efavirenz and cyclosporine [abstract 238].

    Nguyen ME, Tseng A, Conly C, Humar A.   Presented at the 9th Annual Canadian Conference on HIV/AIDS Research, Montreal, PQ.  April 27-30, 2000.

    abstract:  efavcyclo_CAHRabstract[2].doc

Economic implications of non-adherence to HAART in HIV infection [abstract 324].

    Scalera A, Risebrough N, Bayoumi A, Tseng A, Oh P.   Presented at the 9th Annual Canadian Conference on HIV/AIDS Research, Montreal, PQ.  April 27-30, 2000.

    Evidence for immune reconstitution of HIV-specific immunity in HIV seropositive twins receiving HAART, Interleukin-2 and adoptive cellular therapy from their uninfected identical twin.

    Bernard N, Chung F, Goodhew J, Hatzakis G, Kilby D, Kovace C, Luetkehoelter J, Routy, J, Turner H, Walmsley S, Tsoukas CM.   Presented at the 9th Annual Canadian Conference on HIV/AIDS Research, Montreal, April 2000.

Persistence of human papilloma virus in HIV-positive and HIV-negative women associated with immunosuppression and contraceptive practices. 

    Hankins C, Coutlee F, Atkinson M, Girard M, Pourreaux K, Lapointe N, and the Canadian Women's HIV Study Group (S Walmsley, member) . Presented at the 9th Annual Canadian Conference on HIV/AIDS Research, Montreal, April 2000.

A randomized clinical trial of daily multivitamin with or without mixed carotenoid supplementation in advanced HIV disease.

    Austin J, Voigt R, Smaill F, Gill MJ, Walmsley S, Gilmour J, Singer J, Zarowny D, Cameron DW, for the CTN 091/CRIT Carotenoid Study Group.  Presented at the 9th Annual Canadian Conference on HIV/AIDS Research, Montreal, April 2000.

Is combination antiretroviral therapy use increasing in Canadian women?

    Walmsley SL, Hankins C, Atkinson M, Girard M, Pourreaux K, Lapointe N, and the Canadian Women's HIV Study Group.   Presented at the 9th Annual Canadian Conference on HIV/AIDS Research, Montreal, April 2000.

Patient reported complementary and alternative medicine use- An interim assessment of drug utilization patterns for patients attending Ontario HIV outpatient clinics.

    Furler M, Walmsley S, Einarson T, Bendayan R.  Presented at the 9th Annual Canadian Conference on HIV/AIDS Research, Montreal, April 2000.

7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. January 30-February 2, 2000

A pharmacokinetic study of intermittent Dosing of Rifabutin (R) with a Combination of Ritonavir (RV) and Saquinavir (SV) in HIV Patients [abstract 91].

 

Valganciclovir vs IV ganciclovir for newly diagnosed cytomegaloviurs retinitis:  A randomized controlled study [abstract 231].

    Martin D, Sierra-Madero, Walmsley S, Wolitz R, Brown F, Robinson C, and the Roche Valganciclovir Study Group.  Presented at the 7th conference on retroviruses and opportunistic infections. San Francisco, California, Feb 2000.

    abstract:  http://www.retroconference.org/2000/abstracts/231.htm

Evaluation of the Merlin Immediate HIV-1 and -2 test for HIV antibody performed at point of care [abstract 766].

    Shafran S, Prasad E, Zaidi A, Greer J, Vincelette J, Ellis E, Haase D, Walmsley S, Lalonde R, Conway B, Cameron B, and the Canadian HIV POC Test Study Group.   Presented at the 7th conference on retroviruses and opportunistic infections. San Francisco, California, Feb 2000.

    poster:  shafran.retro00.pdf